Summary & Overview
CPT 0317U: LungLB® FISH Blood Assay for Indeterminate Lung Nodules
CPT code 0317U designates LungLB®, a proprietary FISH-based blood test from LungLife AI® that evaluates patients with indeterminate pulmonary nodules identified on imaging. As a PLA code, 0317U applies to this single, manufacturer-specific laboratory assay and is used to stratify nodules as benign or malignant by detecting rare target cells with four FISH probes. This clinical application can influence decisions between invasive biopsy and continued noninvasive monitoring, making it relevant for pulmonology, oncology, and diagnostic laboratory services.
Key payers considered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of the code’s clinical context, typical site of service, and the role of the assay in care pathways for indeterminate lung nodules. The publication also covers payer coverage landscape and benchmark considerations where available, policy and coding guidance updates affecting proprietary laboratory analyses, and implications for lab service lines and hospital outpatient departments. Data not available in the input are noted explicitly where applicable.
Billing Code Overview
CPT code 0317U is a Proprietary Laboratory Analyses (PLA) code assigned specifically to LungLB® from LungLife AI®. The test evaluates a peripheral blood specimen from a patient with an indeterminate lung nodule identified by imaging. Using four fluorescence in situ hybridization (FISH) probes to detect rare target cells associated with lung cancer, the assay stratifies nodules as likely benign or likely cancerous to aid clinician decision-making for biopsy versus noninvasive monitoring.
-
Service type: Laboratory molecular diagnostic test (proprietary FISH-based blood assay)
-
Typical site of service: Clinical laboratory or reference laboratory; specimen collection commonly occurs in an outpatient clinic, phlebotomy center, or hospital outpatient setting.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 66-year-old current or former smoker undergoes chest CT for respiratory symptoms or lung cancer screening and is found to have a 6–20 mm indeterminate pulmonary nodule. The referring pulmonologist or thoracic surgeon orders 0317U (LungLB® from LungLife AI®) on a peripheral blood specimen to aid risk stratification of malignancy when imaging alone is inconclusive and when the clinician is weighing invasive biopsy versus radiologic surveillance. Blood is drawn in the outpatient clinic or ambulatory phlebotomy lab, couriered to the performing laboratory, and processed using the four-probe FISH assay to detect rare circulating tumor-related cells. Laboratory result reporting includes a binary or risk-stratified interpretation (benign vs. cancerous or low/intermediate/high risk) that informs the multidisciplinary discussion and shared decision-making about next steps: percutaneous biopsy, surgical consultation, or interval CT surveillance. Typical sites of service include outpatient clinic, hospital outpatient department, or independent clinical laboratory/phlebotomy center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Modifier not otherwise specified (not a standard CMS modifier) | Use only if payer requires a proprietary two-character code; confirm payer guidance before use. |